Molecular markers in the diagnosis of prostate cancer

被引：16
作者：
van der Poel, H. G. [1 ]
机构：
[1] Netherlands Canc Inst, Dept Urol, NL-1066 CX Amsterdam, Netherlands
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2007年 / 61卷 / 02期
关键词：
prostate cancer; molecular markers; hormone refractory disease; surgery; radiotherapy;
D O I：
10.1016/j.critrevonc.2006.07.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The genetic alterations leading to prostate cancer are gradually being discovered. A wide variety of genes have been associated with prostate cancer development as well as tumor progression. Knowledge of gene polymorphisms associated with disease aid in the understanding of important pathways involved in this process and may result in the near future in clinical applications. Urinary molecular markers will soon be available to aid in the decision of repeat prostate biopsies. Recent findings suggest the importance of androgen signaling in disease development and progression. The further understanding of interaction of inflammation, diet, and genetic predisposition will improve risk stratification in the near future. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：104 / 139
页数：36
相关论文
共 537 条
  • [1] Prognostic value of CD44 standard, variant isoforms 3 and 6 and α-catenin expression in local prostate cancer treated by radical prostatectomy
    Aaltomaa, S
    Lipponen, P
    Viitanen, J
    Kankkunen, JP
    Ala-Opas, M
    Kosma, VM
    [J]. EUROPEAN UROLOGY, 2000, 38 (05) : 555 - 562
  • [2] Aaltomaa S, 1999, PROSTATE, V38, P175
  • [3] Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer
    Aaltomaa, S
    Lipponen, P
    Vesalainen, S
    AlaOpas, M
    Eskelinen, M
    Syrjanen, K
    [J]. EUROPEAN UROLOGY, 1997, 32 (04) : 410 - 415
  • [4] Abrahamsson PA, 1998, PROSTATE, P37
  • [5] Positive correlation between single or combined genotypes of CYP1A1 and GSTM1 in relation to prostate cancer in Chilean people
    Acevedo, C
    Opazo, JL
    Huidobro, C
    Cabezas, J
    Iturrieta, J
    Sepúlveda, LQ
    [J]. PROSTATE, 2003, 57 (02) : 111 - 117
  • [6] URINARY TISSUE FACTOR LEVELS IN PROSTATIC-CARCINOMA - A POTENTIAL MARKER OF METASTATIC SPREAD
    ADAMSON, AS
    FRANCIS, JL
    WITHEROW, RO
    SNELL, ME
    [J]. BRITISH JOURNAL OF UROLOGY, 1993, 71 (05): : 587 - 592
  • [7] Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma
    Adler, HL
    McCurdy, MA
    Kattan, MW
    Timme, TL
    Scardino, PT
    Thompson, TC
    [J]. JOURNAL OF UROLOGY, 1999, 161 (01) : 182 - 187
  • [8] Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence
    Agus, DB
    Cordon-Cardo, C
    Fox, W
    Drobnjak, M
    Koff, A
    Golde, DW
    Scher, HI
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) : 1869 - 1876
  • [9] Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume
    Ahlgren, G
    Pedersen, K
    Lundberg, S
    Aus, G
    Hugosson, J
    Abrahamsson, PA
    [J]. UROLOGY, 2000, 56 (06) : 1011 - 1015
  • [10] Early growth response-1 gene - Potential radiation response gene marker in prostate cancer
    Ahmed, MM
    Chendil, D
    Lele, S
    Venkatasubbarao, K
    Dey, S
    Ritter, M
    Rowland, RG
    Mohiuddin, M
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (05): : 500 - 505
12345678910